Forte Q1 net loss $22.1M; FB102 gets FDA Fast Track; raised $172.5M in April

Forte Biosciences, Inc.

2026-Q1 EPS reported -$1.24

Q1 2026 net loss $22.1M ($1.24 per share); cash $58.2M at March 31, 2026.
FB102 received FDA Fast Track Designation for celiac disease; phase 2 topline results expected in 2026.
Phase 1b vitiligo data expected shortly; alopecia areata data readout in 2026.
R&D expenses rose to $20.5M from $12.7M YoY due to increased clinical and preclinical costs.
In April 2026, raised $172.5M gross via equity offering, issuing 6.6M common shares.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Forte Biosciences, Inc. reported the quarter ended March 31, 2026 results: net income Net loss per share - basic and diluted $ (1.24 ), EPS $(1.24).

Period: the quarter ended March 31, 2026
Net income: Net loss per share - basic and diluted $ (1.24 )
EPS: $(1.24)
Result: reported results

Exact text from the filing

Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Forte Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-224214

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.